OCGN Ocugen, Inc.

0.41
+0.01  (+2%)
Previous Close 0.4
Open 0.41
Price To Book -1.14
Market Cap 14,846,291
Shares 36,201,635
Volume 3,953,164
Short Ratio
Av. Daily Volume 4,811,109
Stock charts supplied by TradingView

NewsSee all news

  1. Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights

    MALVERN, Pa., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  2. Ocugen Announces Warrant Restructuring

    MALVERN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  3. Ocugen Announces Appointments to Retina Disease and Ocular Graft-Versus-Host Disease Scientific Advisory Boards

    MALVERN, Pa., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  4. Ocugen to Host Conference Call on Friday, November 8 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights

    MALVERN, Pa., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  5. Ocugen Announces Share Repurchase Program

    MALVERN, Pa., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN) today announced that its Board of Directors unanimously approved a share repurchase program authorizing the repurchase of up to $2 million in

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

  1. Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights

    MALVERN, Pa., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  2. Ocugen Announces Warrant Restructuring

    MALVERN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  3. Ocugen Announces Appointments to Retina Disease and Ocular Graft-Versus-Host Disease Scientific Advisory Boards

    MALVERN, Pa., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  4. Ocugen to Host Conference Call on Friday, November 8 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights

    MALVERN, Pa., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  5. Ocugen Announces Share Repurchase Program

    MALVERN, Pa., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN) today announced that its Board of Directors unanimously approved a share repurchase program authorizing the repurchase of up to $2 million in

  6. Ocugen Announces Amendment to Asset Purchase Agreement

    MALVERN, Pa., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN) a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  7. Ocugen Appoints Sanjay S. Subramanian, MBA, as Chief Financial Officer

    MALVERN, Pa., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that